The nose being a major compartment for viral infection, and with the high nasal prevalence of the human angiotensin-converting enzyme (ACE2) by which SARS-CoV-2 entry is mediated (Hou et al., 2020), we chose to develop a nasal delivery system to pursue a human nasal hygiene study and compare our pulmonary administration results with nasal delivery. The gene discussed is ACE; the disease is viral infectious disease.